雷沙吉兰
雷沙吉兰(英文:Rasagiline,AZILECT®),一种单胺氧化酶的不可逆抑制剂[1],作为早期帕金森病的治疗单药和作为中、晚期帕金森病 L-多巴(Levodopa) 疗法的附加用药。
![]() | |
![]() | |
| 臨床資料 | |
|---|---|
| 商品名 | Azilect |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a606017 |
| 懷孕分級 |
|
| 给药途径 | Oral |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 藥物動力學數據 | |
| 生物利用度 | 36% |
| 血漿蛋白結合率 | 88 – 94% |
| 药物代谢 | 肝脏代谢 (CYP1A2-mediated) |
| 生物半衰期 | 3 hours |
| 排泄途徑 | 尿液和粪便 |
| 识别 | |
| |
| CAS号 | 1875-50-9 |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.301.709 |
| 化学 | |
| 化学式 | C12H13N |
| 摩尔质量 | 171.238 g/mol |
| 3D模型(JSmol) | |
| |
| |
参考文献
- Oldfield V, Keating GM, Perry CM. . Drugs. 2007, 67 (12): 1725–47. PMID 17683172.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

